A Prospective Double-Blinded Clinical Trial Using Apatone®B for Care and Treatment of Proven Non-Infected Symptomatic Postoperative Total Joint Arthroplasties

This research study is being conducted to determine if taking oral (by mouth in pill form) Apatone®B (a combination of Vitamins C and K3) will reduce chronic joint discomfort and improve function of non-infected symptomatic postoperative total joint replacements.

开始日期2010-10-01

申办/合作机构

Ic Medtech Corp.

[+2]

100 项与 Ic Medtech Corp. 相关的临床结果

登录后查看更多信息

0 项与 Ic Medtech Corp. 相关的专利（医药）

登录后查看更多信息

项与 Ic Medtech Corp. 相关的文献（医药）

2021-12-01·Anticancer Research4区 · 医学

Pharmacological Strategy for Selective Targeting of Glioblastoma by Redox-active Combination Drug – Comparison With the Chemotherapeutic Standard-of-care Temozolomide

4区 · 医学

Article

作者: Shibata, Sayaka ; Aoki, Ichio ; Bakalova, Rumiana ; Zhelev, Zhivko ; Lazarova, Dessislava ; Miller, Thomas ; Zlateva, Genoveva ; Sumiyoshi, Akira

BACKGROUND/AIMWe describe a pharmacological strategy for selectively targeting glioblastoma using a redox-active combination drug menadione/ascorbate (M/A), compared to the chemotherapeutic standard-of-care temozolomide (TMZ).MATERIALS AND METHODSExperiments were conducted on glioblastoma mice (GS9L cell transplants - intracranial model), treated with M/A or TMZ. Tumor growth was monitored by magnetic resonance imaging. Effects of M/A and TMZ on cell viability and overproduction of mitochondrial superoxide were also evaluated on isolated glioblastoma cells (GS9L) and normal microglial cells (EOC2).RESULTSM/A treatment suppressed tumor growth and increased survival without adverse drug-related side effects that were characteristic of TMZ. Survival was comparable with that of TMZ at the doses we have tested so far, although the effect of M/A on tumor growth was less pronounced than that of TMZ. M/A induced highly specific cytotoxicity accompanied by dose-dependent overproduction of mitochondrial superoxide in glioblastoma cells, but not in normal microglial cells.CONCLUSIONM/A differentiates glioblastoma cells from normal microglial cells, causing redox alterations and oxidative stress only in the tumor. This easier-to-tolerate treatment has a potential to support the surgery and conventional therapy of glioblastoma.

Cancers2区 · 医学

Targeting Glioblastoma via Selective Alteration of Mitochondrial Redox State

2区 · 医学

ArticleOA

作者: Sumiyoshi, Akira ; Higashi, Tatsuya ; Obata, Takayuki ; Miller, Thomas ; Lazarova, Dessislava ; Zhelev, Zhivko ; Aoki, Ichio ; Bakalova, Rumiana ; Shibata, Sayaka

Glioblastoma is one of the most aggressive brain tumors, characterized by a pronounced redox imbalance, expressed in a high oxidative capacity of cancer cells due to their elevated glycolytic and mitochondrial oxidative metabolism. The assessment and modulation of the redox state of glioblastoma are crucial factors that can provide highly specific targeting and treatment. Our study describes a pharmacological strategy for targeting glioblastoma using a redox-active combination drug. The experiments were conducted in vivo on glioblastoma mice (intracranial model) and in vitro on cell lines (cancer and normal) treated with the redox cycling pair menadione/ascorbate (M/A). The following parameters were analyzed in vivo using MRI or ex vivo on tissue and blood specimens: tumor growth, survival, cerebral perfusion, cellular density, tissue redox state, expression of tumor-associated NADH oxidase (tNOX) and transforming growth factor-beta 1 (TGF-β1). Dose-dependent effects of M/A on cell viability, mitochondrial functionality, and redox homeostasis were evaluated in vitro. M/A treatment suppressed tumor growth and significantly increased survival without adverse side effects. This was accompanied by increased oxidative stress, decreased reducing capacity, and decreased cellular density in the tumor only, as well as increased cerebral perfusion and down-regulation of tNOX and TGF-β1. M/A induced selective cytotoxicity and overproduction of mitochondrial superoxide in isolated glioblastoma cells, but not in normal microglial cells. This was accompanied by a significant decrease in the over-reduced state of cancer cells and impairment of their “pro-oncogenic” functionality, assessed by dose-dependent decreases in: NADH, NAD+, succinate, glutathione, cellular reducing capacity, mitochondrial potential, steady-state ATP, and tNOX expression. The safety of M/A on normal cells was compromised by treatment with cerivastatin, a non-specific prenyltransferase inhibitor. In conclusion, M/A differentiates glioblastoma cells and tissues from normal cells and tissues by redox targeting, causing severe oxidative stress only in the tumor. The mechanism is complex and most likely involves prenylation of menadione in normal cells, but not in cancer cells, modulation of the immune response, a decrease in drug resistance, and a potential role in sensitizing glioblastoma to conventional chemotherapy.

项与 Ic Medtech Corp. 相关的新闻（医药）

2022-11-25

·Business Wire

2022 Polycystic Kidney Disease Drugs in Development Report: Featuring Angion Biomedica, ATLAS Molecular Pharma, Bristol-Myers Squibb and Camurus Among Others - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Polycystic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering. This publisher's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Drugs In Development, 2022, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape. Companies Mentioned AceLink Therapeutics Inc Amathus Therapeutics Inc AmMax Bio Inc Angion Biomedica Corp ATLAS Molecular Pharma SL Bristol-Myers Squibb Co Camurus AB Centessa Pharmaceuticals Plc Chimerna Therapeutics Inc Chinook Therapeutics Inc DiscoveryBiomed Inc Eloxx Pharmaceuticals Inc Galapagos NV Generian Pharmaceuticals Inc GLG Pharma SA Goldfinch Bio Inc Healx Ltd IC-MedTech Inc Ipsen SA Johnson & Johnson Kadmon Holdings Inc ManRos Therapeutics Mironid Ltd Mitotherapeutix LLC Otsuka Pharmaceutical Co Ltd Pano Therapeutics Inc Poxel SA Reata Pharmaceuticals Inc Regulus Therapeutics Inc Shanghai Alebund Pharmaceuticals Ltd Surrozen Inc XORTX Therapeutics Inc Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. The report provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 3, 18 and 14 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively. Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders). The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) Reasons to Buy Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information about this report visit https://www.researchandmarkets.com/r/ii4537

临床2期

2021-01-05

·GlobeNewswire

Chronic Kidney Disease (CKD) Pipeline Insight, 2020 Report Featuring 55 Key players & 10 Key Products

Dublin, Dec. 31, 2020 (GLOBE NEWSWIRE) -- The "Chronic Kidney Disease (CKD) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. The "Chronic Kidney Disease (CKD) - Pipeline Insight, 2020," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Chronic Kidney Disease Emerging Drugs Chapters This segment of the Chronic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Chronic Kidney Disease Emerging Drugs AZD5718: AstraZeneca AstraZeneca is conducting a study to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease. The study will be conducted in approximately 118 study centers across 12 countries. The overall study period will be around 28 weeks. Approximately 632 participants comprising of 67% diabetic kidney disease (DKD) and 33% non-DKD participants will be enrolled. DDO-3055: Jiangsu HengRui Medicine Co., Ltd. Jiangsu HengRui Medicine is conducting a randomized, double-blind, dose-escalating, placebo controlled, phase I study to evaluate the safety and pharmacokinetics and pharmacodynamics of DDO-3055 in healthy volunteers and patients with Chronic Kidney Disease. This is a randomized, double-blind, dose-escalating, placebo controlled, Phase I study to evaluate the safety, pharmacokinetics and pharmacodynamics of DDO-3055 in healthy volunteers and patients with chronic kidney disease. 48 healthy volunteers will be enrolled in Part A, and 18 patients with chronic kidney disease will be enrolled in Part B. Chronic Kidney Disease: Therapeutic Assessment This segment of the report provides insights about the different Chronic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Chronic Kidney Disease There are approx. 50+ key companies which are developing the therapies for Chronic Kidney Disease. The companies which have their Chronic Kidney Disease drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, AstraZeneca, UnicoCell Biomed, Jiangsu Hansoh Pharmaceutical, Bio Sidus, Keryx Biopharmaceuticals, AMAG Pharmaceuticals, inRegen, AbbVie etc. Phases The report covers around 50+ products under different phases of clinical development like Mid-stage products (Phase II and Phase I/II) Early-stage products (Phase I/II and Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Intramuscular Molecule Type Products have been categorized under various Molecule types such as Small molecules Proteins and peptides Polymers Diamines Chlorinated hydrocarbons Product Type Drugs have been categorized under various product types like Mono, Combination and Mono/Combination. Chronic Kidney Disease: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Kidney Disease therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Kidney Disease drugs. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Kidney Disease. August 2020: DAPA-CKD trial meets primary endpoint in patients with chronic kidney disease. Dapagliflozin reduces the risk of kidney failure, death from cardiovascular causes or heart failure hospitalisation and all-cause mortality in chronic kidney disease patients with or without type 2 diabetes. That's the main result of the DAPA-CKD trial presented in a Hot Line session today at ESC Congress 2020. Chronic Kidney Disease Report Insights Chronic Kidney Disease Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Chronic Kidney Disease Report Assessment Pipeline Product Profiles Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Key Questions Current Treatment Scenario and Emerging Therapies: How many companies are developing Chronic Kidney Disease drugs? How many Chronic Kidney Disease drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Kidney Disease? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Chronic Kidney Disease and their status? What are the key designations that have been granted to the emerging drugs? Key Players AdAlta Ltd Allena Pharmaceuticals Inc apceth Biopharma GmbH Arch Biopartners Inc Astellas Pharma Inc AstraZeneca Plc Bayer AG BiOrion Technologies BV Boehringer Ingelheim GmbH Boryung Pharmaceutical Co Ltd Celgene Corp Certa Therapeutics Pty Ltd Conatus Pharmaceuticals Inc Corvidia Therapeutics Inc DiaMedica Therapeutics Inc Dimerix Bioscience Pty Ltd DiscoveryBiomed Inc DURECT Corp Epigen Biosciences Inc Galectin Therapeutics Inc GenKyoTex SA GNI Group Ltd iBio Inc IC-MedTech Inc Ipsen SA Isarna Therapeutics GmbH KBP BioSciences Co Ltd Kidney Fibrosis Klotho Therapeutics Inc Les Laboratoires Servier SAS ManRos Therapeutics Mironid Ltd NovaTarg Therapeutics Inc Novo Nordisk AS OPKO Health Inc Opsidio LLC Otsuka Holdings Co Ltd Pharmaxis Ltd Q BioMed Inc Redx Pharma Plc Regulus Therapeutics Inc Resverlogix Corp Sanwa Kagaku Kenkyusho Co Ltd Sarfez Pharmaceuticals Inc Scholar Rock Inc Sirnaomics Inc Sphaera Pharma Pte Ltd Symic Biomedical Inc Taisho Pharmaceutical Holdings Co Ltd Theravance Biopharma Inc Unity Biotechnology Inc Vascular Biogenics Ltd Vascular BioSciences VESSL Therapeutics Ltd Vicore Pharma AB Key Products AZD5718 MEDI8367 efepoetin alfa Verinurad Empagliflozin DDO-3055 KBP-5074 Doxercalciferol TRC101 Pegol-Sihematide For more information about this drug pipelines report visit Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

小分子药物并购合作

100 项与 Ic Medtech Corp. 相关的药物交易

登录后查看更多信息

100 项与 Ic Medtech Corp. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

维生素C/甲萘醌 ( NF-κB )	前列腺癌更多	临床2期
ICM20	-	临床1期
KST-401	肿瘤更多	无进展
KST-301	感染更多	无进展
KST-213	肿瘤更多	无进展